The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Eli Lilly lands an $870 million pact with Camurus to build long-acting obesity treatments, tapping FluidCrystalslow-release ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

For shareholders there's no better conclusion, as it implies a consistent revenue stream from each new patient ... Still, it's hard to deny that Eli Lilly's stock keeps getting sweeter as it ...

Continue » Given the potential opportunities in the sector, should investors buy Eli Lilly stock? Here's where the ... after a trial patient experienced a liver injury while taking it.

Sales of Trulicity are also being hurt by patient switches to Mounjaro ... deeper to understand whether to buy, sell or hold Lilly’s stock. Lilly’s stock has risen 14.8% so far this year ...

The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering ...

The stock of U.S. pharmaceutical giant Eli Lilly (LLY) is up 3% on news that ... Pfizer said it is ending work on the pill after a patient experienced a liver injury during the drug’s trial.

Eli Lilly (NYSE: LLY) is the most valuable healthcare company in the world, worth more than $700 billion. Over the past 12 months, however, the stock's performance has been fairly lackluster ...

The stock's rise snapped a five-day losing streak.

Shares of Eli Lilly (LLY) jumped 16% Thursday morning ... Rocket Pharmaceuticals Stock Craters After Gene Therapy Patient Dies Moderna Stock Jumps on New FDA COVID-19 Booster Guidelines Novavax ...